NIH Pressured to Keep CAR-T Therapy Affordable Before Granting License

Drug Industry Daily
Advocacy groups are urging the National Institutes of Health (NIH) to keep a lid on the price of a CAR-T therapy if it decides to give an exclusive license to a group of former venture capital firm members.

To View This Article:


Subscribe To Drug Industry Daily